The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis

• Published in: International immunopharmacology 2020-10, Vol.87, p.106852-106852, Article 106852
• Main Authors: Yi, Kun, Zhu, Qian, Kuang, Yu-Kang, Jiang, Si-Cong, Hu, Hao
• Format: Article
• Language: English
• Subjects: Apoptosis; Clinical trials; Death; Epidermal growth factor receptors; Inhibitors; Ligands; Lung cancer; Meta-analysis; Mortality; Mutation; Non-small cell lung carcinoma; Non-small-cell lung cancer; Overall survival; Patients; PD-1 protein; PD-L1 protein; Programmed death ligand 1; Programmed death receptor-1; Receptors; Small cell lung carcinoma; Smoking; Therapy
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2020.106852

[Display omitted] •PD-1 and PD-L1 inhibitors significantly extended OS compared with standard of care therapy in advanced NSCLC.•Superior relative and absolute OS benefits in patients treated with PD-1 inhibitors than in patients treated with PD-L1 inhibitors.•The same increased OS benefit was observed regardless of PD-L1 status. Programmed death receptor-1 (PD-1) and its ligand (PD-L1) inhibitors have shown promising results in treating advanced non-small-cell lung cancer (NSCLC). Our objective was to compare the relative and absolute benefits between PD-1 and PD-L1 inhibitors in advanced NSCLC. PubMed, EMBASE and the Cochrane Library were searched up to Dec 1, 2019, for randomized controlled trials of PD-1/PD-L1 inhibitors that had available overall survival (OS) data in NSCLC. Random-effects models were used to calculate the pooled estimates. Twenty-three randomized controlled trials (15,797 patients) of PD-1/PD-L1 inhibitors were included in the analysis. PD-1 inhibitors significantly extended OS compared with standard of care therapy (difference in means, 4.80 months, 95% CI 3.41–6.18; HR 0.72, 95% CI 0.66–0.78; P